These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33681528)

  • 1. Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials.
    Takahashi A; Suzuki T
    Contemp Clin Trials Commun; 2021 Mar; 21():100753. PubMed ID: 33681528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
    Diniz MA; Quanlin-Li ; Tighiouart M
    J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hierarchical models for sharing information across populations in phase I dose-escalation studies.
    Cunanan KM; Koopmeiners JS
    Stat Methods Med Res; 2018 Nov; 27(11):3447-3459. PubMed ID: 28480828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A curve free Bayesian decision-theoretic design for phase Ia/Ib trials considering both safety and efficacy outcomes.
    Fan S; Lee BL; Lu Y
    Stat Biosci; 2020 Jul; 12(2):146-166. PubMed ID: 33815623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies.
    Kakizume T; Morita S
    Ther Innov Regul Sci; 2014 Mar; 48(2):213-219. PubMed ID: 30227515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
    Diniz MA; Kim S; Tighiouart M
    Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.